Skip to main content
Clinical Trials/ACTRN12612000288820
ACTRN12612000288820
Completed
Phase 3

Optimising management of acute pain in opioid substitution therapy patients: A pilot laboratory randomised study.

Sydney Local Health District - Royal Prince Alfred Hospital0 sites21 target enrollmentStarted: March 12, 2012Last updated:

Overview

Phase
Phase 3
Status
Completed
Sponsor
Sydney Local Health District - Royal Prince Alfred Hospital
Enrollment
21

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Randomised controlled trial
Primary Purpose
Treatment
Masking
Blinded (masking used)

Eligibility Criteria

Ages
18 Years to 65 Years (—)
Sex
All

Inclusion Criteria

  • (1\) patients with stable OST dose for \>4weeks (methadone and buprenorphine groups)
  • or opiate naive ie have never been dependent on opiates and have not used any opiates in the last 4 weeks (control group);
  • (2\) participants opioid substitution dose between 40\-100mg of methadone or 8\-24mg buprenorphine;
  • (3\) aged 18 – 65 yrs; and
  • (4\) participants give informed consent

Exclusion Criteria

  • (1\) severe acute medical or psychiatric conditions
  • (2\) pregnancy
  • (3\) are currently using or dependent to other substances such as alcohol, benzodiazepines, cocaine, psychostimulants or heroin;
  • (4\) moderate or severe pain within 4 weeks prior to the study
  • (5\) are currently participating in another research project that may interfere with the present study;
  • (6\) on medications with significant pharmacokinetic/dynamic interaction with study medications
  • (7\) cold urticaria
  • Eligible participants will be deemed healthy by the study physician. Participants with a current pain condition will be excluded from the study as concurrent pain conditions may confound the results from the cold pressor test, which is being used as a model for acure pain. One arm of the study involves healthy volunteers, and the other two arms of the study are a group pf patients on methadone and a group of patients on buprenorphine.

Investigators

Sponsor
Sydney Local Health District - Royal Prince Alfred Hospital

Similar Trials